These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16625144)

  • 21. Clinical application of deferasirox: practical patient management.
    Vichinsky E
    Am J Hematol; 2008 May; 83(5):398-402. PubMed ID: 18058997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.
    Vichinsky E; Bernaudin F; Forni GL; Gardner R; Hassell K; Heeney MM; Inusa B; Kutlar A; Lane P; Mathias L; Porter J; Tebbi C; Wilson F; Griffel L; Deng W; Giannone V; Coates T
    Br J Haematol; 2011 Aug; 154(3):387-97. PubMed ID: 21592110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferasirox : a review of its use in the management of transfusional chronic iron overload.
    Yang LP; Keam SJ; Keating GM
    Drugs; 2007; 67(15):2211-30. PubMed ID: 17927285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iron chelation therapy for myelodysplastic syndrome: if and when.
    Tefferi A
    Mayo Clin Proc; 2006 Feb; 81(2):197-8. PubMed ID: 16471074
    [No Abstract]   [Full Text] [Related]  

  • 25. Deferasirox and children: From clinical trials to the real world.
    Origa R; Zappu A; Foschini ML; Leoni G; Morittu M; Moi P; Corpino M; Dessì C
    Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
    Chen CH; Shu KH; Yang Y
    Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
    Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
    Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
    Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferasirox for transfusion-related iron overload: a clinical review.
    Lindsey WT; Olin BR
    Clin Ther; 2007 Oct; 29(10):2154-66. PubMed ID: 18042472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
    Fragomeno C; Roccabruna E; D'Ascola DG
    Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pharmaco-economic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan.
    Ho WL; Chung KP; Yang SS; Lu MY; Jou ST; Chang HH; Yang YL; Lin DT; Lin KH
    J Formos Med Assoc; 2013 Apr; 112(4):221-9. PubMed ID: 23537869
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes.
    Ricchi P; Marsella M
    Drug Des Devel Ther; 2015; 9():6475-82. PubMed ID: 26719673
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lower-risk, transfusion-dependent myelodysplastic syndrome patients.
    Tolley K; Oliver N; Miranda E; Migliaccio-Walle K; Bozkaya D; Li Q
    J Med Econ; 2010; 13(3):559-70. PubMed ID: 20812793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of medication adherence on the effectiveness of deferasirox for the treatment of transfusional iron overload in myelodysplastic syndrome.
    Escudero-Vilaplana V; Garcia-Gonzalez X; Osorio-Prendes S; Romero-Jimenez RM; Sanjurjo-Saez M
    J Clin Pharm Ther; 2016 Feb; 41(1):59-63. PubMed ID: 26778738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Deferasirox: a review of its use for chronic iron overload in patients with non-transfusion-dependent thalassaemia.
    Shirley M; Plosker GL
    Drugs; 2014 Jun; 74(9):1017-27. PubMed ID: 24919862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Deferasirox: for iron overload: only a third-line option.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17929382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deferasirox (Exjade) for the treatment of iron overload.
    Cappellini MD; Taher A
    Acta Haematol; 2009; 122(2-3):165-73. PubMed ID: 19907154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.